CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 88 enrolled
Drug / intervention
Insulin Regular +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00690534
NCT00690534Phase 1Completed
CompareCT.gov

Insulin and Sarcopenia in the Elderly

The University of Texas Medical Branch, Galveston·interventional·Posted Jun 4, 2008·Updated Dec 12, 2016

In Brief

A Phase 1 clinical trial evaluating Insulin Regular, L-NMMA, and 2 other interventions for Sarcopenia. Completed, enrolled 88 participants across 1 site.

Detailed Summary

Muscle loss with aging is a significant contributor to disability in older people. Our general hypothesis is that loss of muscle with aging, known as sarcopenia, may be due to inability of muscle to grow in response to insulin. Our goal is to determine the mechanisms underlying this age-related insulin resistance of muscle proteins, which will allow us to define in the future specific interventions to target this defect and provide the scientific basis for the prevention and treatment of sarcopenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcopenia
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 4, 2008
Enrollment StartSep 1, 2005
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 18.1 years ago

Interventions

Insulin Regulardrug

insulin, 0.2 mU/kg/min for 3 hours

L-NMMAdrug

variable rate for 3 hours

Sodium Nitroprussidedrug

variable rate for 3 hours

mixed mealother

mixed meal